Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab Plus Chemotherapy and Sequential Osimertinib in EGFR-Mutated NSCLC
NCT06142617Phase 2Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Dec 2023
- Primary completion
- Nov 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Peking Union Medical College Hospital. Primary endpoint: Progression Free Survival 1 at 8 weeks. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT06142617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06142617.